Navigation auf uzh.ch
Navigation auf uzh.ch
From Earth to Space to Earth: From Regenerative Medicine to Biodiversity – Science from Switzerland
The Institute for Regenerative Medicine, which has the mission to advance molecular life sciences into next generation therapies, established recently the iPSC Core Facility to promote this powerful technology at the UZH and other institutions.
New insights into the biology of an aggressive pediatric cancer, which will help focus future research goals.
"From the bench to clinical trials for a regeneration enhancing anti-Nogo-A antibody therapy for spinal cord injury"
The Institute for Regenerative Medicine (IREM) is pleased to share the news that the U.S. Food and Drug Administration (FDA) has approved aducanumab for the treatment of Alzheimer’s disease. Alzheimer’s disease is the most common form of dementia and accounts for 50-75% of all cases worldwide.
"Geometry influences inflammatory host cell response and remodeling in tissue-engineered heart valves in-vivo”
“Rethinking multi-organ tissue-engineering: an in-vitro model to design regenerative native-like tissue-engineered heart valves”
"Characterization of the Blood Brain Barrier Disruption in the Photothrombotic Stroke Model"
We welcome Professor Sandra Loerakker as a Visiting Professor at our institute.
In order to underpin its position among the world’s leading research institutions, the University of Zurich has established its University Research Priority Programs (URPP). The URPP create and promote academic networks in selected areas of research and contribute to the advancement of knowledge in areas of research that benefit society.
New paper by Michele Filippo Buono, Lisa von Boehmer, Jaan Strang, Simon P. Hoerstrup, Maximilian Y. Emmert and Bramasta Nugraha, published on 20 July
Anna S Wahl, Daphne Correa et.al. on ‘Targeting Therapeutic Antibodies to the CNS: A Comparative Study of Intrathecal, Intravenous, and Subcutaneous Anti-Nogo A Antibody Treatment after Stroke in Rats’, published in Neurotherapeutics
Once every year, around 30-40 Nobel Laureates and 600 excellent, young scientists from all around the world convene in Lindau, to foster the exchange among scientists of different generations, cultures and disciplines. This year’s 70th Nobel Laureate Meeting is an interdisciplinary meeting, where scientists from all three natural sciences – chemistry, physic and medicine – are united.
Stroke remains a major cause of serious disability due to the brain’s limited capacity to regenerate.
Prof. Dr. Janine Reichenbach has started as associate professor for Somatic Gene Therapy at the Institute for Regenerative Medicine (IREM), chairing this new division of the institute.
Autoimmune diseases and cancer have highly interesting parallels that can be used for novel therapeutic approaches. Tumours that originate from endocrine (hormone-producing) organs such as the thyroid gland, the parathyroid gland, the pituitary gland or the gastrointestinal tract are often characterised by excessive hormone production and frequently retain the functional and molecular properties of their originating organ.
IREM Professor Max Emmert received the Techno-College Innovation Award for the LifeMatrix, a human cell derived acellular engineered tissue platform.
In this study, we demonstrate that antibody-mediated Nogo-A neutralization following stroke has strong pro-angiogenic effects but does not increase vascular permeability as opposed to the Vascular Endothelial Growth Factor (VEGF). Moreover, VEGF-induced vascular permeability was partially prevented when VEGF was co-administered with anti-Nogo-A antibodies. This study may provide a novel therapeutic strategy for vascular repair and maturation in the ischemic brain.
In July 2019, the SNSF launched the funding scheme Spark as a pilot project to support unconventional research and novel scientific approaches. Each application was evaluated in a double-blind procedure by two members of an international pool of experts. It was the idea that counted most of all. Other important criteria were the quality of the submitted project proposal and the potential impact of the results.
We are delighted to announce that the first iPSC lecture will take place at the University of Zurich. This lecture series will provide a forum to disseminate state-of-the-art iPSC research, build relationships with one-another, renew and establish collaborations and strategies. Experts in the field of iPSC technology will share their knowledge.
October 23, 2019 -- IREM is pleased to learn that Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on a new analysis of a larger data set from Phase 3 studies. Neurimmune, a spin-out company of the University of Zurich, discovered aducanumab together with a research group at the University of Zurich that went on to co-found IREM. In 2007 Neurimmune and Biogen entered into a collaborative development and license agreement for aducanumab's development and commercialization.
Viele Schlankheitsmittel sind gesundheitsschädlich oder zu wenig wirksam. Nun entwickelt ein Startup der UZH einen Appetithemmer, der keine unerwünschten Nebenwirkungen hervorruft und das Gewicht im Vergleich zu zugelassenen Standardmedikamenten im Tiermodell doppelt so stark reduziert.
The International Symposium for Applied Cardiovascular Biology and Vascular Tissue Engineering (ISACB+ISVTE) has successfully come to an end.
Following a stroke, antibodies that inhibit the signaling molecule Nogo-A can help repair blood vessels in the affected brain regions. This also promotes the regaining of motor functions, researchers at the University of Zurich have shown in a mouse model. The study opens up new avenues for treatment.
“Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential" by Kehl et al. was published in Nature Regenerative Medicine
We welcome Professor Frank Baaijens as a Visiting Professor at our institute.
medAlumni, an organization of alumni of the medical faculty of UZH had their annual meeting at our institute.
This year's topic was "Regenerative Medizin in der Forschung und die unternehmerische Umsetzung".
IREM scientist accepted as full member and group leader
IREM scientist awarded for clinical research
Alzheimer disease (AD) is characterized by wide heterogeneity in cognitive and behavioural syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic variation will be crucial for the development of precise and effective therapeutics in AD.
On 18 May, the European Commission (EC) announced that the FET Flagship RESTORE, which was initiated by the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), has been selected to enter the next phase of the FET Flagship competition. A successful FET Flagship will eventually receive around EUR 1 billion for ten years by the EC (9th research framework program) and other sponsors to enable groundbreaking research projects. The research initiative RESTORE has been selected as one of five proposals in the field of "Health and Life Sciences" and is now working with stakeholders to refine its extended concept for the second selection round later this year.
Using computer simulations, researchers developed heart valves that regenerate and grow with the body.
In addition to its core responsibilities in research and teaching, the University of Zurich provides targeted funding for innovative projects. With its new BioEntrepreneur Fellowships, UZH supports junior researchers in adapting scholarly findings and technologies for commercial use. And thanks to a generous donation, UZH is now able to expand the program.
Herzfehler behandeln mit Prothesen, die wachsen und sich regenerieren – das ist das Ziel des kardiovaskulären Tissue Engineering. Gemeinsam haben nun Forschende der Universität Zürich, der Technischen Universität Eindhoven und der Charité Berlin zum ersten Mal erfolgreich regenerative Herzklappen bei Schafen eingesetzt, die mithilfe von Computersimulationen designt wurden.
This year's winners of the Pfizer Research Awards include seven researchers from the University of Zurich and the University's hospitals.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease.
Zürich - Der Grossraum Zürich hat diejenigen Trümpfe, die es für einen erfolgreichen Biotechnologie-Standort benötigt, sagt Roger Nitsch, Präsident des Schlieremer Unternehmens Neurimmune. Er hat die guten Köpfe und die Infrastruktur, darunter gerade auch den Bio-Technopark Schlieren-Zürich.
At the end of May, the executive board and UZH researchers spent two days in Boston. The trip was designed to foster relationships and build new cooperation arrangements with Harvard University, the Massachusetts Institute of Technology (MIT), and other institutions in the Greater Boston Area.
Harvard’s Wyss Institute and the University of Zurich partner to create a next-generation heart valve that accurately functions upon implantation and regenerates into long-lasting heart-like tissue
(19.04.2017, Neue Zürcher Zeitung) Künstliche Herzklappen wachsen nicht. Um wiederholte Eingriffe bei Kindern zu vermeiden, haben Forscher einen wachsenden Herzklappenersatz entwickelt. Nach 20 Jahren Forschung stehen sie vor ersten Tests im Mensch.
Foreign Policy Magazine recognizes Prof. R. Nitsch as one of the "Top 100 Global Thinkers 2016"
Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease. These protein deposits in the brain are a classic sign of Alzheimer's disease and contribute to the progressive degeneration of brain cells. The researchers furthermore demonstrated in an early stage clinical study that, after one year of treatment with Aducanumab, cognitive decline could be significantly slowed in antibody-treated patients as opposed to the placebo group.
Using tissue engineering different roads can lead towards the same goal. One of these is the 3D printer, which can be used printing structures such as noses and ears. / Bei der Gewebezüchtung führen verschiedene Wege zum Ziel. Einer davon ist der 3D-Drucker, mit dem bereits einfache Gewebe wie Nasen und Ohren ausgedruckt werden können.
The LifeMatrix project (tissue-engineered human matrix technology for the treatment of children with congenital heart disease) has been presented by the Wyss Zurich towards leading experts from Imperial College London. Challenges of the clinical translation in regenerative medicine at the Royal Society of Medicine has been discussed. / Das LifeMatrix Projekt (Künstlich hergestellte menschliche Gewebematrix für die Behandlung von Kindern mit angeborenen Herzerkrankungen) wurde von Vertretern des Wyss Zürich gegenüber führenden Experten vom Imperial College London vorgestellt. Dabei wurden Herausforderungen der klinischen Translation in der regenerativen Medizin an der "Royal Society of Medicine" diskutiert.
Prof. Emmert receives science award in recognition of his scientific and clinical activity in the field of cardiovascular regenerative medicine. Main research interests are the tissue engineering of heart valves with growth and regeneration potential and the cardiac stem cell therapy. Mr. Emmert is next to his clinical work at the University Hospital research group leader at the Institute for Regenerative Medicine (www.irem.uzh.ch ) and Co - Director of the Life Matrix project at Wyss Translational Center Zurich (www.wysszurich.uzh.ch/). / Prof. Emmert erhält den Wissenschaftspreis in Anerkennung seiner wissenschaftlichen und klinischen Tätigkeit im Bereich der kardiovaskulären Regenerativen Medizin. Hauptforschungsschwerpunkte sind das Tissue engineering von Herzklappen mit Wachstums- und Regenerationspotenzial sowie die kardiale Stammzelltherapie. Herr Emmert ist neben seiner klinischen Tätigkeit am Universitätsspital Forschungsgruppenleiter am Institut für Regenerative Medizin (www.irem.uzh.ch) und Co-Leiter des LifeMatrix Projektes am Wyss Translational Center Zürich (www.wysszurich.uzh.ch/).
ETH Zurich and the University of Zurich found a new translational research center at the interface of medicine, science and engineering. / Die ETH Zürich und die Universität Zürich gründen ein neues translationales Forschungszentrum an der Schnittstelle von Medizin, Natur- und Ingenieurwissenschaften.
Defective heart valves can now be easily replaced. However, in children and young adults implants show several limitations. One solution is expected from tissue engineering. / Defekte Herzklappen lassen sich heute problemlos austauschen. Doch bei Kindern und jungen Erwachsenen stossen die Implantate an Grenzen. Einen Ausweg erhofft man sich von der Gewebezucht.
The Wyss Institute at Harvard University and the University of Zurich announced today the signing of a cooperation agreement / Das Wyss Institute der Harvard University und die Universität Zürich geben heute die Unterzeichnung eines Kooperationsvertrages bekannt.
At the Swiss Center for Regenerative Medicine researchers are working on heart valves for babies. Such an innovation could improve the quality of life of many children. The bred heart valve could replace the artificial valve. / Im Schweizer Zentrum für Regenerative Medizin wird an einer Herzklappe für Babys gearbeitet. Eine solche Neuerung könnte die Lebensqualität vieler Kinder verbessern. Die gezüchtete könnte die künstliche Klappe ablösen.
A team fro Zurich tests bred cell clumps on pigs / Zürcher Team testet gezüchtete Zellklumpen an Schweinen.
For the first time human stem cells have been successfully cloned. Biologist Sebastian Jessberger reports about replacement organs on the bench, personalized medicine and ethical concerns. / Erstmals in der Geschichte wurden menschliche Stammzellen erfolgreich geklont. Biologe Sebastian Jessberger über Ersatzorgane auf dem Labortisch, individuelle Medizin und ethische Bedenken.
Doctors have a child transplanted a vein, which they previously have been bred from stem cells. This and other examples show that tissue engineering works in the bloodstream. / Ärzte haben einem Kind eine Vene transplantiert, die sie aus Stammzellen züchteten. Dieses und weitere Beispiele zeigen, dass Tissue-Engineering im Blutkreislauf funktioniert.
Why does future medicine focus on regenerative tissue engineering? / Weshalb setzt die Zukunftsmedizin auf die regenerative Gewebezüchtung?
Under the 7th Framework Program (FP7-HEALTH-2009-single-stage), the Commission of the European Union has authorized the official launch of the project "Life VALVE" up from 1 November 2009. This is the third substantial promotion of the research program "Regenerative Medicine" at the University Hospital Zurich and the University of Zurich in the current year. / Im Rahmen des 7. Framework Program (FP7-HEALTH-2009-single-stage) hat die Kommission der Europäischen Union den offiziellen Start des Forschungsprojektes „Life VALVE” zum 1. November 2009 autorisiert. Es ist dies die dritte substantielle Förderung des Forschungsschwerpunktes „Regenerative Medizin“ am Universitäts-Spital Zürich und an der Universität Zürich im laufenden Jahr.
